Hans Clevers MD PhD is director of the Hubrecht Laboratory/Netherlands Institute of Developmental Biology.
He received his MD from the University of Utrecht in 1984 and his PhD from the same university in 1985 studying signal transduction in T lymphocytes. For his postdoctoral training he joined the group of C. Terhorst at the Harvard-affiliated Dana-Farber Cancer Institute to work on the molecular biology of the TCR/CD3 complex of T lymphocytes. In 1989 he returned to the University of Utrecht to initiate a program in transcriptional regulators of T cell development and became professor and chairman of the Department of Immunology at the Faculty of Medicine, Utrecht University in 1991. Hans has authorized numerous publications in leading journals as Nature, Science and Cell. Together with his colleague, professor Ton Logtenberg, he founded U-BiSys, in 1996, a phage display technology company and LSP investment that, after it merged with IntroGene, another LSP investment, was listed at both NASDAQ and Euronext (Amsterdam) in October 2000 under the name Crucell (ticker symbol: "CRXL"). In 2000 he became a member of the Royal Dutch Academy of Sciences (KNAW). In October 2001 he co-founded, with LSP's Tom Schwarz and four leading scientists in Germany and the Netherlands , the drug discovery company Semaia Pharmaceuticals B.V. In 2001 he was awarded the prestigious Spinoza prize and in 2004 the Louis-Jantet prize for his research in the field of cancer. Within the LSP organization, Hans actively participates in LSP's deal meetings, provides access to his vast scientific network, assesses the majority of business plans that meet LSP's general investment criteria, and is instrumental in providing LSP with an active deal flow.